Referencias a artículos incluidos en PubMed que los socios consideren de especial interés. Si deseas colaborar, envía la referencia recomendada, indicando tu nombre y centro de trabajo, a la siguiente dirección de correo electrónico:

• Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan;142(1):63-70.e5  [PubMed]
  [20-2-2012. José Joaquín Ramírez. Hospital Lluis Alcanyis, Xàtiva]

• Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012 May 11. doi: 10.1002/hep.25831. [Epub ahead of print]  [PubMed] 
  [12-5-2012. Joaquín Primo. Hospital de Sagunto]

• Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012 Jun;19(6):377-86.  [PubMed]  
  [12-5-2012. Joaquín Primo. Hospital de Sagunto]

• Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. J Viral Hepat. 2012 Apr;19(4):244-253.  [PubMed]
  [13-4-2012. Joaquín Primo. Hospital de Sagunto]

• Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012 Feb 1. doi: 10.1111/j.1365-2036.2012.04992.x. [Epub ahead of print]  [PubMed] 
  [7-2-2012. Joaquín Primo. Hospital de Sagunto]

• Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011 Nov;54(5):1538-46.  [PubMed]
  [30-1-2012. Joaquín Primo. Hospital de Sagunto]